As we move closer to the implementation of the Affordable Care Act, there are still many unanswered questions as to how things will work, challenges from all sides of the political spectrum and healthcare industry, and a lot of misinformation floating around as well. This week, in our Homerun Slides, we …
Read More »Monthly Archives: September 2013
Affordable Care Act, Part 1 of 3
This we begin a terrific series of Homerun Slides for you on the Afforable Care Act. This first set will cover the Primary Drivers of Healthcare Reform, and then give a brief overview of the goals of the ACA….
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #36: Psychological Issues in the Treatment of Diabetes, Part 1 of 3
Barbara J. Anderson, PhD, CDE and Abigail K. Mansfield Marcaccio, PhD This week’s excerpt answers the following questions: How do you screen patients for psychological issues at diagnosis of diabetes? When can you use the terms "a touch of sugar" and "borderline diabetes"? How important is it to address misconceptions …
Read More »AHRQ ePSS
U.S. Department of Health & Human Services Free iOS/Android The Electronic Preventive Services Selector (ePSS) is an application designed and developed by the U.S. Department of Health & Human Services (HHS), Agency for Healthcare Research and Quality (AHRQ), the nation’s leading federal agency for research on health care quality, …
Read More »Letter from the Editor, #694: Why Some Obese Patients Don’t Get Diabetes
We have seen numerous studies demonstrating the value of resistance exercise for diabetes patients but often we only think of weights and machines and those methods rule out a lot of our patients. This week, Dr. Sheri Colberg brings us a primer on how all our patients can do some …
Read More »Resistance Training for Everyone
By Sheri Colberg, PhD The goal of resistance training is increased muscular fitness, both muscular strength and endurance.
Read More »Sanofi Withdrawing NDA for Lixisenatide
Sanofi Withdrawing NDA for Lixisenatide Sanofi announced they are withdrawing their New Drug Application (NDA) for their once-daily GLP-1 lixisenatide from the FDA. The combination of lixisenatide and Lantus® (basal insulin), the investigational LixiLan fixed-ratio product, remains on schedule to enter into phase 3 in the first half of 2014.
Read More »Diabetes and Social Security
Diabetes and Social Security For your patients with diabetes who need financial assistance we have this PDF for you: Diabetes and Social Security Benefits
Read More »Pro Therapy System
Pro Therapy System Cupron, Inc. has announced the development of an antifungal sock for patients with diabetes called the Pro Therapy System. Made with copper, the antifungal technology is embedded in the fibers of the sock, and as a result, its effectiveness will not diminish over time. The sock effectively …
Read More »Acarbose Improves GLP-1 Effects on Newly Diagnosed Type 2 Patients
The benefits of acarbose on cardiovascular risk may be related to its stimulation of GLP-1 secretion. Blood was drawn from 24 subjects with drug-naïve T2D at 0 and 120 min following a standard mixed meal to measure active GLP-1, NO and NOS. The CIMT was measured prior to and following …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.